mRNA technology was quickly adopted in the COVID-19 vaccine race and has undoubtedly proven its worth. Less than a year after the emergence of COVID-19, an entirely new type of vaccine based on ...

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results.

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory ... allowing rival vaccines from Pfizer/BioNTech and Modera to dominate the category.